Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis
Thaís Armangue,Marianna Spatola,Alexandru Vlagea,Simone Mattozzi,Marc Cárceles-Cordon,Eloy Martinez-Heras,Sara Llufriu,Jordi Muchart,María Elena Erro,Laura Abraira,German Moris,Luis Monros-Giménez,Íñigo Corral-Corral,Carmen Montejo,Manuel Toledo,Luis Bataller,Gabriela Secondi,Helena Ariño,Eugenia Martínez-Hernández,Manel Juan,Maria Angeles Marcos,Laia Alsina,Albert Saiz,Myrna R Rosenfeld,Francesc Graus,Josep Dalmau,Spanish Herpes Simplex Encephalitis Study Group,Sergio Aguilera-Albesa,Alfonso Amado-Puentes,Antonio Arjona-Padillo,Luisa Arrabal,Izascun Arratibel,Gemma Aznar-Laín,Paula Bellas-Lamas,Teresa Bermejo,Sabas Boyero-Durán,Ana Camacho,Andrea Campo,Dulce Campos,Verónica Cantarín-Extremera,Cristóbal Carnero,David Conejo-Moreno,Marta Dapena,David Dacruz-Álvarez,Verónica Delgadillo-Chilavert,Angela Deyà,Jordi Estela-Herrero,Anna Felipe,Elisa Fernández-Cooke,Joaquín Fernández-Ramos,Claudia Fortuny,Juan C García-Monco,Teresa Gili,Verónica González-Álvarez,Robert Guerri,Sara Guillén,Antonio Hedrera-Fernández,María López,Eduardo López-Laso,María Lorenzo-Ruiz,Marcos Madruga,Ignacio Málaga-Diéguez,Itxaso Martí-Carrera,Xavier Martínez-Lacasa,Lucía Martín-Viota,Leticia Martín Gil,María-Jesús Martínez-González,Antia Moreira,María C Miranda-Herrero,Lorena Monge,Beatriz Muñoz-Cabello,Juan Navarro-Morón,Olaf Neth,Antoni Noguera-Julian,Noemí Nuñez-Enamorado,Virginia Pomar,Juan C Portillo-Cuenca,María Poyato,Luis Prieto,Luis Querol,Eloy Rodríguez-Rodríguez,Silvana Sarria-Estrada,Concepción Sierra,Pere Soler-Palacín,Víctor Soto-Insuga,Laura Toledo-Bravo,Miguel Tomás,Carmen Torres-Torres,Eulàlia Turón,Ana Zabalza
DOI: https://doi.org/10.1016/S1474-4422(18)30244-8
Abstract:Background: Herpes simplex encephalitis can trigger autoimmune encephalitis that leads to neurological worsening. We aimed to assess the frequency, symptoms, risk factors, and outcomes of this complication. Methods: We did a prospective observational study and retrospective analysis. In the prospective observational part of this study, we included patients with herpes simplex encephalitis diagnosed by neurologists, paediatricians, or infectious disease specialists in 19 secondary and tertiary Spanish centres (Cohort A). Outpatient follow-up was at 2, 6, and 12 months from onset of herpes simplex encephalitis. We studied another group of patients retrospectively, when they developed autoimmune encephalitis after herpes simplex encephalitis (Cohort B). We compared demographics and clinical features of patients who developed autoimmune encephalitis with those who did not, and in patients who developed autoimmune encephalitis we compared these features by age group (patients ≤4 years compared with patients >4 years). We also used multivariable binary logistic regression models to assess risk factors for autoimmune encephalitis after herpes simplex encephalitis. Findings: Between Jan 1, 2014, and Oct 31, 2017, 54 patients with herpes simplex encephalitis were recruited to Cohort A, and 51 were included in the analysis (median age 50 years [IQR 5-68]). At onset of herpes simplex encephalitis, none of the 51 patients had antibodies to neuronal antigens; during follow-up, 14 (27%) patients developed autoimmune encephalitis and all 14 (100%) had neuronal antibodies (nine [64%] had NMDA receptor [NMDAR] antibodies and five [36%] had other antibodies) at or before onset of symptoms. The other 37 patients did not develop autoimmune encephalitis, although 11 (30%) developed antibodies (n=3 to NMDAR, n=8 to unknown antigens; p<0·001). Antibody detection within 3 weeks of herpes simplex encephalitis was a risk factor for autoimmune encephalitis (odds ratio [OR] 11·5, 95% CI 2·7-48·8; p<0·001). Between Oct 7, 2011, and Oct 31, 2017, there were 48 patients in Cohort B with new-onset or worsening neurological symptoms not caused by herpes simplex virus reactivation (median age 8·8 years [IQR 1·1-44·2]; n=27 male); 44 (92%) patients had antibody-confirmed autoimmune encephalitis (34 had NMDAR antibodies and ten had other antibodies). In both cohorts (n=58 patients with antibody-confirmed autoimmune encephalitis), patients older than 4 years frequently presented with psychosis (18 [58%] of 31; younger children not assessable). Compared with patients older than 4 years, patients aged 4 years or younger (n=27) were more likely to have shorter intervals between onset of herpes simplex encephalitis and onset of autoimmune encephalitis (median 26 days [IQR 24-32] vs 43 days [25-54]; p=0·0073), choreoathetosis (27 [100%] of 27 vs 0 of 31; p<0·001), decreased level of consciousness (26 [96%] of 27 vs seven [23%] of 31; p<0·001), NMDAR antibodies (24 [89%] of 27 vs 19 [61%] of 31; p=0·033), and worse outcome at 1 year (median modified Rankin Scale 4 [IQR 4-4] vs 2 [2-3]; p<0·0010; seizures 12 [63%] of 19 vs three [13%] of 23; p=0·001). Interpretation: The results of our prospective study show that autoimmune encephalitis occurred in 27% of patients with herpes simplex encephalitis. It was associated with development of neuronal antibodies and usually presented within 2 months after treatment of herpes simplex encephalitis; the symptoms were age-dependent, and the neurological outcome was worse in young children. Prompt diagnosis is important because patients, primarily those older than 4 years, can respond to immunotherapy. Funding: Mutua Madrileña Foundation, Fondation de l'Université de Lausanne et Centre Hospitalier Universitaire Vaudois, Instituto Carlos III, CIBERER, National Institutes of Health, Generalitat de Catalunya, Fundació CELLEX.